Overview

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Status:
Recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Phase:
Phase 3
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.
Treatments:
Seladelpar